» Articles » PMID: 17096325

Inflammation and IGF-I Activate the Akt Pathway in Breast Cancer

Overview
Journal Int J Cancer
Specialty Oncology
Date 2006 Nov 11
PMID 17096325
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Akt signaling may promote breast cancer progression and poor disease outcome. We hypothesized that serum insulin-like growth factor I (IGF-I) and a proinflammatory tumor environment induce phosphorylation of Akt and downstream targets of Akt in breast cancer. We studied the relationship between Akt pathway activation, IGF-I and markers of inflammation, e.g., nitric oxide synthase-2 (NOS2), cyclooxygenase-2 (COX2) and tumor phagocyte density, in 248 breast tumors. We also examined the association of Akt phosphorylation with breast cancer survival. We observed that phosphorylation of Akt, BAD and caspase-9 correlated strongly with the expression of the 2 proinflammatory enzymes, NOS2 and COX2, in breast tumors (p < 0.001; Spearman rank correlation). Both NOS2 and COX2 expression were independently associated with Akt phosphorylation in the multivariate analysis. Serum IGF-I concentrations and the IGF-I/IGFBP3 ratio correlated with Akt phosphorylation at Thr308 and Ser473 in breast tumors (p <or= 0.05; Spearman rank correlation). The association with Akt phosphorylation at Thr308 remained statistically significant in the multivariate analysis. Akt pathway activation was not associated with overall survival in the unstratified analysis, but we observed a statistical interaction between Akt phosphorylation and tumor phagocyte density on breast cancer survival (p(interaction) < 0.05). We further corroborated our findings in cell culture models by demonstrating that ANA-1 macrophages, nitric oxide and prostaglandin E(2) induce Akt phosphorylation in human breast cancer cells. In summary, a proinflammatory environment was found to activate the Akt pathway in breast cancer, and may modify the association between the Akt phosphorylation status and breast cancer survival.

Citing Articles

Nitric oxide inhibits ten-eleven translocation DNA demethylases to regulate 5mC and 5hmC across the genome.

Palczewski M, Kuschman H, Hoffman B, Kathiresan V, Yang H, Glynn S Nat Commun. 2025; 16(1):1732.

PMID: 39966373 PMC: 11836389. DOI: 10.1038/s41467-025-56928-1.


Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer.

Mussa A, Ismail N, Hamid M, Al-Hatamleh M, Bragoli A, Hajissa K J Exp Clin Cancer Res. 2024; 43(1):312.

PMID: 39609700 PMC: 11603874. DOI: 10.1186/s13046-024-03218-1.


NOS2 and COX-2 Co-Expression Promotes Cancer Progression: A Potential Target for Developing Agents to Prevent or Treat Highly Aggressive Breast Cancer.

Coutinho L, Femino E, Gonzalez A, Moffat R, Heinz W, Cheng R Int J Mol Sci. 2024; 25(11).

PMID: 38892290 PMC: 11173351. DOI: 10.3390/ijms25116103.


Nitric oxide inhibits ten-eleven translocation DNA demethylases to regulate 5mC and 5hmC across the genome.

Thomas D, Palczewski M, Kuschman H, Hoffman B, Yang H, Glynn S Res Sq. 2024; .

PMID: 38645113 PMC: 11030528. DOI: 10.21203/rs.3.rs-4131804/v1.


Diabetes-associated breast cancer is molecularly distinct and shows a DNA damage repair deficiency.

Panigrahi G, Candia J, Dorsey T, Tang W, Ohara Y, Byun J JCI Insight. 2023; 8(23).

PMID: 37906280 PMC: 10795835. DOI: 10.1172/jci.insight.170105.